- Home
- CANF vs SOHO Comparison
CANF vs SOHO Comparison
Compare CANF & SOHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SOHO
- Stock Information
- Founded
- CANF 1994
- SOHO 2004
- Country
- CANF Israel
- SOHO United States
- Employees
- CANF N/A
- SOHO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SOHO Real Estate Investment Trusts
- Sector
- CANF Health Care
- SOHO Real Estate
- Exchange
- CANF Nasdaq
- SOHO Nasdaq
- Market Cap
- CANF 13.5M
- SOHO 15.4M
- IPO Year
- CANF N/A
- SOHO 2004
- Fundamental
- Price
- CANF $1.03
- SOHO $0.88
- Analyst Decision
- CANF Strong Buy
- SOHO Hold
- Analyst Count
- CANF 2
- SOHO 1
- Target Price
- CANF $14.00
- SOHO $1.50
- AVG Volume (30 Days)
- CANF 141.2K
- SOHO 43.2K
- Earning Date
- CANF 08-29-2025
- SOHO 08-12-2025
- Dividend Yield
- CANF N/A
- SOHO N/A
- EPS Growth
- CANF N/A
- SOHO N/A
- EPS
- CANF N/A
- SOHO N/A
- Revenue
- CANF $674,000.00
- SOHO $182,158,199.00
- Revenue This Year
- CANF $461.72
- SOHO $13.93
- Revenue Next Year
- CANF N/A
- SOHO N/A
- P/E Ratio
- CANF N/A
- SOHO N/A
- Revenue Growth
- CANF N/A
- SOHO 3.11
- 52 Week Low
- CANF $0.98
- SOHO $0.59
- 52 Week High
- CANF $4.69
- SOHO $1.54
- Technical
- Relative Strength Index (RSI)
- CANF 41.84
- SOHO 46.26
- Support Level
- CANF $1.00
- SOHO $0.83
- Resistance Level
- CANF $1.05
- SOHO $1.04
- Average True Range (ATR)
- CANF 0.03
- SOHO 0.08
- MACD
- CANF 0.00
- SOHO -0.02
- Stochastic Oscillator
- CANF 40.00
- SOHO 22.22
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.